Skyrizi
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Skyrizi in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Skyrizi.
14
Global Revenue Ranking
6
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Skyrizi
The form of inflammatory bowel disease is estimated to affect five million people globally
The inflammatory bowel disease affects more than one million people in the US
Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology
The evolved brand includes the company’s first-ever brand claim, Life Forward
The late-stage trial has been evaluating the IL-23 inhibitor against Johnson & Johnson’s Stelara
The late-stage study has been evaluating the drug against Johnson & Johnson’s Stelara
Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US
The approval makes Skyrizi the first specific IL-23 inhibitor as a Crohn’s treatment in the EU
Mizrahi joins the agency from her role as executive creative director at FCB Health NY
IL-23 blocker mirikizumab helped patients achieve clinical remission in 12-week induction study
Consumer groups and public interest organisations raise new concerns
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology